The Largest Biotech City in Europe Will Soon Be Built

The entire BIO CITY complex will span an area equivalent to 10 football fields, total investment expected to reach around 7 billion euros

06-Dec-2023 - Northway Group is embarking on a project to establish Europe’s largest biotechnology hub, BIO CITY, in Vilnius, the capital of Lithuania. It includes 6 large biotechnological complexes – 4 state-of-the-art GMP manufacturing plants and 2 advanced scientific research centres – that will be built in ...

Merck to Become First Provider to Offer Fully Integrated mRNA Services

New sites at Darmstadt and Hamburg complement Merck’s global integrated mRNA service network

28-Sep-2023 - Merck became the first CTDMO (contract testing, development and manufacturing organization) to offer integrated services for all critical stages of mRNA development, manufacturing, and commercialization, including products and testing. The company opened two new GMP-grade mRNA drug substance ...

Merck Completes Acquisition of Exelead and Plans to Invest More Than € 500 Million in Technology Scale-Up

Company now offers comprehensive end-to-end services across mRNA value chain

24-Feb-2022 - Merck announced the closing of the transaction to acquire Exelead, following regulatory clearances and the fulfillment of other customary closing conditions, for approximately USD780million in cash. The business combination is expected to enable Merck’s Life Science business sector to provide ...

Definitive Agreement to Acquire Exelead will Strengthen Merck’s CDMO Offering for mRNA

Targeted acquisition to accelerate novel modalities service offering

07-Jan-2022 - Merck has signed a definitive agreement to acquire Exelead, a biopharmaceutical contract development and manufacturing organization (CDMO), for approximately USD780million in cash. Exelead specializes in complex injectable formulations, including Lipid Nanoparticle (LNP) based drug delivery ...

Merck Completes New Viral Vector Contract Development Manufacturing Facility for Gene Therapy

Growth through investments in the “Big 3”

13-Oct-2021 - Merck announced the opening of its second Carlsbad, California-based facility, significantly expanding its global CDMO footprint. This new €100 million, 140,000-square foot facility will more than double the company’s existing capacity to support large-scale commercial and industrial ...

Lonza and Chr. Hansen in Joint Venture to Accelerate Momentum in Microbiome

Phased investment of approximately EUR 90 million

04-Apr-2019 - Chr. Hansen Holding A/S and Lonza AG have signed an agreement to establish a 50/50 joint venture to pioneer the live biotherapeutic products (LBPs) industry and position themselves as the leading contract development and manufacturing partner (CDMO) for biotech and pharma customers. The joint ...

Celonic Acquires Glycotope’s Bio-manufacturing Facility

03-Nov-2017 - Celonic AG and Glycotope announced the successful completion of Celonic’s acquisition of Glycotope’sbio-manufacturing facility in Heidelberg, Germany. The acquisition is in line with Celonic’s vision to strengthen its position as a premier global player in the high-growth CDMO market, with ...

Eurofins expands in India

Acquires biopharmaceutical company Advinus from Tata Group

27-Jul-2017 - Eurofins Scientific announces that it has signed an exclusive agreement with Tata Group to acquire Advinus Therapeutics, a preclinical and clinical phase contract research company for Safety Assessment, DMPK, CMC services, and Analytical R&D Services. The transaction is expected to close in the ...

AGC acquires a leading German biopharmaceutical CMO

07-Sep-2016 - AGC Asahi Glass, a world-leading manufacturer of glass, chemicals and high-tech materials, announces that it has acquired all of the shares of Biomeva GmbH (Biomeva) from Biomeva Holding GmbH. Biomeva is one of the leading biopharmaceutical contract manufacturing organizations (CMO) in Europe. ...

Companies opt for CMOs offering high-quality services

26-Nov-2013 - The global contract manufacturing market is growing steadily with firms allocating up to four percent of annual organization revenues for contract manufacturing organization (CMO) services, with a likely markup to 11 percent within the next three years. On average, firms partner with six CMOs, ...